Sener EF, Oztop DB, Ozkul Y
[Google Scholar] 9.Chun LJ, Tong MJ, Busuttil RW, et al
Transitioning to more sustainable food systems that support health and wellbeing
GHK-Cu starts low and steps up mid-cycle
They care about safe and responsible distribution of these products to advance peptide research
Legitimate Research Directions: Some peptides DO have potential and are being properly studied: Thymosin Alpha-1: Immune support (approved in 35+ countries, trials in US) BPC-157: IF proper human trials ever happen LL-37: Antimicrobial applications Others: Many peptides have theoretical promise But ONLY if studied properly: Randomized controlled trials Safety studies FDA approval process Medical supervision The Problem: Most "wellness peptides" will NEVER go through this process because: They can't be patented (no profit incentive) Companies would rather sell in gray market Proper trials cost $100M+ If trials show they DON'T work, the market disappears So we're stuck in limbo: promising animal data, zero human data, aggressive marketing